Company intelligence / Profile preview

CIS entities

Bubendorf, Basel-Landschaft, Switzerland

Ownership: Private
Employees: ~25
Development stage: Other

Overview

CIS Pharma is a Swiss biopharmaceutical company specializing in the development of innovative therapies for ophthalmology and oncology. The company leverages its proprietary Cell-Targeting-Polymer (CTP) platform to create targeted drug delivery systems that improve the efficacy and safety of existing and new therapeutic agents. Their pipeline includes advanced treatments for dry eye syndrome and glaucoma, as well as targeted conjugates for solid tumors. By combining polymer chemistry with biological targeting, CIS Pharma aims to address significant unmet medical needs through precision medicine.

Therapeutic areas: OncologyOphthalmology
Modalities: Small moleculePeptidesPolymer-drug conjugate therapyAntibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on CIS entities.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIS entities.

Explore the full profile